Cardiovascular disease (CVD) stands as the world’s leading cause of morbidity and mortality and is also the most resource-intensive for healthcare systems to manage. Despite recent advances in its treatment, more effective and accessible ways to tackle CVDs remain to be discovered. Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) takes on the challenge to develop new ways to treat CVD with innovative technologies allowing early prediction and intervention. These technologies not only reduce the human cost but also alleviate financial and social burden on the healthcare system. 

 

In collaboration with the University of Oxford and the Karolinska Institutet, COCHE was established under City University of Hong Kong in 2020. COCHE is supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme, a major R&D initiative of the Hong Kong Special Administrative Region Government. We are developing high-sensitive quantifiable CVD biomarker detection systems, real-time cerebro-cardiovascular health assessment and warning systems, advanced technology for precision diagnostic system, and enhanced therapeutic system. All data we collect is systematically integrated into our CVD database together with other biomarkers, driving revolutionary improvements in the global prevention and treatment of cerebrocardiovascular diseases.